Posted by Michael Wonder on 19 Jul 2024
Phathom Pharmaceuticals announces FDA approval of Voquenza (vonoprazan) tablets for the relief of heartburn associated with non-erosive GERD in adults
18 July 2024 - Voquenza met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment.
Phathom Pharmaceuticals announced today the US FDA has approved Voquenza (vonoprazan) 10 mg tablets for the relief of heartburn associated with non-erosive gastro-esophageal reflux disease in adults.
